Little Dog client Epic Sciences announced new data supporting the finding that the Oncotype DX AR-V7 Nucleus Detect blood test is the first test that can predict treatment response and demonstrate a survival benefit for men who have metastatic castration-resistant prostate cancer.  

This multi-institutional cohort study was published recently in the journal JAMA Oncology. 

This test, available through Genomic Health and developed by Epic Sciences, can tell doctors whether a patient will respond to hormone therapy or if they need to switch to chemotherapy.  

Read more at Xconomy. 

Pin It on Pinterest